|

anti CD19 CAR NK cells Clinical Trials

2 actively recruiting trials

Pipeline

Early 1: 1Phase 1: 1

Top Sponsors

  • The First Affiliated Hospital with Nanjing Medical University1
  • Second Affiliated Hospital, School of Medicine, Zhejiang University1

Indications

  • Antisynthetase Syndrome1
  • Systemic Lupus Erythematosus1
  • Lupus1
  • Arthritis1
  • Rheumatoid Arthritis1

Other2 trials

An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis
Early 1
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.